Molecular genetics of high-risk chronic lymphocytic leukemia

Expert Review of Hematology

Volumn 5, Issue 6, 2012, Pages 593-602

  Rossi, Davide ^a   Gaidano, Gianluca ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

17p13 deletion; BIRC3; chemorefractoriness; chronic lymphocytic leukemia; high risk mutations; NOTCH1; SF3B1; TP53

Indexed keywords

AMINO ACID; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; FLUDARABINE; GAMMA SECRETASE INHIBITOR; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; METALLOPROTEINASE INHIBITOR; MYC PROTEIN; NOTCH1 RECEPTOR; PROLINE; PROTEIN; PROTEIN BIRC3; PROTEIN P53; PROTEIN SF3B1; RITUXIMAB; SERINE; SMALL NUCLEAR RIBONUCLEOPROTEIN; THREONINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; B LYMPHOCYTE; BIRC3 GENE; CARBOXY TERMINAL SEQUENCE; CELL MATURATION; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DNA BINDING; DNA REPAIR; DNA SEQUENCE; EMBRYO DEVELOPMENT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE DELETION; GENE DISRUPTION; GENE MUTATION; GENETIC DISORDER; HIGH RISK PATIENT; HUMAN; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENESCENCE; SF3B1 GENE; STEM CELL; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870954803     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.58     Document Type: Review

References (78)

1. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2010, 481-488 (2010).
2. Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 119(18), 4101-4107 (2012).
3. Dreger P, Corradini P, Kimby E et al.; Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21(1), 12-17 (2007).
4. Hallek M, Fischer K, Fingerle-Rowson G et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
5. Zenz T, Eichhorst B, Busch R et al. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol. 28(29), 4473-4479 (2010).
6. Catovsky D, Richards S, Matutes E et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370(9583), 230-239 (2007).
7. Gonzalez D, Martinez P, Wade R et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 Trial. J. Clin. Oncol. 29(16), 2223-2229 (2011).
8. Stilgenbauer S, Zenz T, Winkler D et al. German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27(24), 3994-4001 (2009).
9. Zenz T, Häbe S, Denzel T et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114(13), 2589-2597 (2009).
10. Fabbri G, Rasi S, Rossi D et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208(7), 1389-1401 (2011).
11. Puente XS, Pinyol M, Quesada V et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475(7354), 101-105 (2011).
12. Quesada V, Conde L, Villamor N et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44(1), 47-52 (2012).
13. Rossi D, Bruscaggin A, Spina V et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118(26), 6904-6908 (2011).
14. Wang L, Lawrence MS, Wan Y et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365(26), 2497-2506 (2011).
15. Sportoletti P, Baldoni S, Cavalli L et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br. J. Haematol. 151(4), 404-406 (2010).
16. Rossi D, Rasi S, Fabbri G et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119(2), 521-529 (2012).
17. Rossi D, Fangazio M, Rasi S et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119(12), 2854-2862 (2012).
18. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9(12), 862-873 (2009).
19. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910-1916 (2000).
20. Zenz T, Kröber A, Scherer K et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112(8), 3322-3329 (2008).
21. Dicker F, Herholz H, Schnittger S et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23(1), 117-124 (2009).
22. Malcikova J, Smardova J, Rocnova L et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 114(26), 5307-5314 (2009).
23. Rossi D, Cerri M, Deambrogi C et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin. Cancer Res. 15(3), 995-1004 (2009).
24. Rossi D, Spina V, Deambrogi C et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117(12), 3391-3401 (2011).
25. Zainuddin N, Murray F, Kanduri M et al. TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk. Res. 35(2), 272-274 (2011).
26. Zenz T, Vollmer D, Trbusek M et al. European Research Initiative on CLL (ERIC). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 24(12), 2072-2079 (2010).
27. Tam CS, Shanafelt TD, Wierda WG et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 114(5), 957-964 (2009).
28. Eichhorst BF, Busch R, Hopfinger G et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3), 885-891 (2006).
29. Bosch F, Abrisqueta P, Villamor N et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J. Clin. Oncol. 27(27), 4578-4584 (2009).
30. Schlette EJ, Admirand J, Wierda W et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk. Lymphoma 50(10), 1597-1605 (2009).
31. Trbusek M, Smardova J, Malcikova J et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J. Clin. Oncol. 29(19), 2703-2708 (2011).
32. Marinelli M, Raponi S, Del Giudice I et al. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia? Am. J. Clin. Pathol. 135(1), 173-174 (2011).
33. Hallek M, Cheson BD, Catovsky D et al.; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute - Working Group 1996 guidelines. Blood 111(12), 5446-5456 (2008).
34. Pospisilova S, Gonzalez D, Malcikova J et al. European Research Initiative on CLL (ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26(7), 1458-1461 (2012).
35. Dreger P, Döhner H, Ritgen M et al. German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116(14), 2438-2447 (2010).
36. Pettitt AR, Jackson R, Carruthers S et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 trial. J. Clin. Oncol. 30(14), 1647-1655 (2012).
37. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 208(10), 1931-1935 (2011).
38. Yuan JS, Kousis PC, Suliman S, Visan I, Guidos CJ. Functions of notch signaling in the immune system: consensus and controversies. Annu. Rev. Immunol. 28, 343-365 (2010).
39. Rothenberg EV. T cell lineage commitment: identity and renunciation. J. Immunol. 186(12), 6649-6655 (2011).
40. Santos MA, Sarmento LM, Rebelo M et al. Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc. Natl Acad. Sci. USA 104(39), 15454-15459 (2007).
41. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J. Pathol. 223(2), 262-273 (2011).
42. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 25(2), 83-90 (2011).
43. Balatti V, Bottoni A, Palamarchuk A et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 119(2), 329-331 (2012).
44. Del Giudice I, Rossi D, Chiaretti S et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 97(3), 437-441 (2012).
45. López C, Delgado J, Costa D et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer 51(9), 881-889 (2012).
46. Rosati E, Sabatini R, Rampino G et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 113(4), 856-865 (2009).
47. Rasi S, Monti S, Spina V, Foà R, Gaidano G, Rossi D. Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. Haematologica 97(1), 153-154 (2012).
48. Rossi D, Rasi S, Spina V et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br. J. Haematol. 158(3), 426-429 (2012).
49. Groth C, Fortini ME. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin. Cell Dev. Biol. 23(4), 465-472 (2012).
50. Will CL, Lührmann R. Spliceosome structure and function. Cold Spring Harb. Perspect. Biol. 3(7), a003707 (2011).
51. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24(21), 2343-2364 (2010).
52. Luke MM, Della Seta F, Di Como CJ, Sugimoto H, Kobayashi R, Arndt KT. The SAP, a new family of proteins, associate and function positively with the SIT4 phosphatase. Mol. Cell. Biol. 16(6), 2744-2755 (1996).
53. Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev. 12(10), 1409-1414 (1998).
54. Das BK, Xia L, Palandjian L, Gozani O, Chyung Y, Reed R. Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. Mol. Cell. Biol. 19(10), 6796-6802 (1999).
55. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 136(4), 701-718 (2009).
56. Papaemmanuil E, Cazzola M, Boultwood J et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365(15), 1384-1395 (2011).
57. Yoshida K, Sanada M, Shiraishi Y et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367), 64-69 (2011).
58. Greco M, Capello D, Bruscaggin A et al. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis. Hematol. Oncol. doi: 10.1002/hon.2013 (2012) (Epub ahead of print).
59. Spitali P, Aartsma-Rus A. Splice modulating therapies for human disease. Cell 148(6), 1085-1088 (2012).
60. Kern C, Cornuel JF, Billard C et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103(2), 679-688 (2004).
61. Endo T, Nishio M, Enzler T et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway. Blood 109(2), 703-710 (2007).
62. Hewamana S, Alghazal S, Lin TT et al. The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111(9), 4681-4689 (2008).
63. Buggins AG, Pepper C, Patten PE et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-κB activation and de novo gene transcription. Cancer Res. 70(19), 7523-7533 (2010).
64. Herishanu Y, Pérez-Galán P, Liu D et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117(2), 563-574 (2011).
65. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693-733 (2009).
66. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416(6878), 345-347 (2002).
67. Zarnegar BJ, Wang Y, Mahoney DJ et al. Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9(12), 1371-1378 (2008).
68. Conze DB, Zhao Y, Ashwell JD. Noncanonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biol. 8(10), e1000518 (2010).
69. Rossi D, Deaglio S, Dominguez-Sola D et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood 118(18), 4930-4934 (2011).
70. Stilgenbauer S, Liebisch P, James MR et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc. Natl Acad. Sci. USA 93(21), 11837-11841 (1996).
71. Schaffner C, Stilgenbauer S, Rappold GA, Döhner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 94(2), 748-753 (1999).
72. Austen B, Powell JE, Alvi A et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106(9), 3175-3182 (2005).
73. Guarini A, Marinelli M, Tavolaro S et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 97(1), 47-55 (2012).
74. Skowronska A, Austen B, Powell JE et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica 97(1), 142-146 (2012).
75. Hewamana S, Lin TT, Jenkins C et al. The novel nuclear factor-κB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin. Cancer Res. 14(24), 8102-8111 (2008).
76. Hertlein E, Wagner AJ, Jones J et al. 17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 116(1), 45-53 (2010).
77. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6), 1175-1184 (2012).
78. Cheson BD, Byrd JC, Rai KR et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J. Clin. Oncol. 30(23), 2820-2822 (2012).